Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 1
Submit an article Journal homepage
110
Views
50
CrossRef citations to date
0
Altmetric
Review

Hepatitis B mother-to-child transmission

Sylvie Ranger-Rogez Department of Virology, EA3175 MENR, CHRU Dupuytren, 2 av. Martin Luther King, 87042 Limoges Cédex, France. [email protected]
&
Fran¸ois Denis Department of Virology, EA3175 MENR, CHRU Dupuytren, 2 av. Martin Luther King, 87042 Limoges Cédex, France. [email protected]
Pages 133-145 | Published online: 10 Jan 2014

References

  • MacCallum FO, Bauer DJ. Homologous serum hepatitis. Lancet ii, 691–692 (1947).
  • Blumberg BS, Alter HJ. A 'new' antigen in leukemic serum. JAMA 191,541–546 (1967).
  • Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1, 695–698 (1970).
  • •First report demonstrating the relationship between hepatitis B (known to be associated with Australia-antigen) and viral particles.
  • Mahoney FJ. Update on diagnosis, management and prevention of hepatitis B virus infection. Clin. Microbiol. Rev. 12, 351–366 (1999).
  • •Valuable review of hepatitis B infection, that gives a detailed account of the different methods for disease control.
  • Koff RS. Prevention of Viral Hepatitis. Carr. Treat. Options Gastroenterol. 5, 451–463 (2002).
  • Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 342, 1335–1340 (1993).
  • Chang MH, Hsu HY, Ni YH, et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. J. HepatoL 28, 915–922 (1998).
  • Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin. Infect. Dis. 20,992–1000 (1995).
  • Boxall E. Screening of pregnant women for hepatitis B. Vaccine 16 (Suppl.), S30-33 (1998).
  • McMahon BJ, Alberts SR, Wainwright RB, Bulkow L and Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch. Intern. Med. 150, 1051–1054 (1990).
  • Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann. Intern. Med. 108,390–401 (1988).
  • Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2,395–403 (2002).
  • Oda T. Viral hepatitis and hepatocellular carcinoma prevention strategy in Japan. Japan J. Cancer Res. 90,1051–1060 (1999).
  • Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 18 (Suppl. 1), S20-22 (2000).
  • Khuroo MS and Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J. Viral Hepat. 10, 61–69 (2003).
  • Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine 18 (Suppl. 1), S17-19 (2000).
  • Poovorawan Y, Chongsrisawat V, Theamboonlers A, Vimolkej L, Yano M. Is there evidence for intrauterine HBV infection in newborns of hepatitis B carrier mothers? SoutheastAsianj Trop. Med. Public Health28, 365–369 (1997).
  • Xu DZ, Yan YP, Choi BC, et al Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study.. 1. Med. Virol. 67,20-26 (2002).
  • •This paper clearly demonstrates a transplacental leakage of maternal blood in intrauterine infection with a cellular transfer of HBV from cell to cell in the placenta.
  • Wang Z, Zhang J, Yang H, et al Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies.. 1. Med. Vim]. 71, 360–366 (2003).
  • Towers CV, Asrat T, Rumney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am. j Obstet. GynecoL 184, 1514–1518; discussion 1518–1520 (2001).
  • Alexander JM, Ramus R, Jackson G, Sercely B, Wendel GD Jr. Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. Infect. Dis. Obstet. GynecoL 7, 283–286 (1999).
  • •The authors show the absence of HBV transmission by amniocentesis in 21 pregnant women who are HBV carriers.
  • Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med. J115, 1510–1512 (2002).
  • Shiraki K. Perinatal transmission of hepatitis B virus and its prevention.. 1. GastroenteroL HepatoL 15 (Suppl.), Eli—is (2000).
  • Sterneck M, Kalinina T, Otto S, et al Neonatal fulminant hepatitis B: structural and functional analysis of complete hepatitis B virus genomes from mother and infant.. 1. Infect. Dis. 177, 1378–1381 (1998).
  • Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet. GynecoL 99, 1049–1052 (2002).
  • Wang JS, Zhu QR, Wang XH. Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HBV carrier mothers. Int.. 1. Cilia. Pratt 57, 100–102 (2003).
  • Ordog K, Szendroi A, Szarka K, et al Perinatal and intrafamily transmission of hepatitis B virus in three generations of a low-prevalence population.. 1. Med. Virol. 70, 194–204 (2003).
  • Chang MH. Hepatitis B: long-term outcome and benefits from mass vaccination in children. Acta GastroenteroL Belg. 61, 210–213 (1998).
  • Maupas P, Goudeau A, Coursaget P, Drucker J and Bagros P Immunization against hepatitis B in man. Lancet 1,1367–1370 (1976).
  • Barn F, Goudeau A, Denis F, et al. Immune response in neonates to hepatitis B vaccine. Lancetl, 251–253 (1982).
  • Belloni C, Avanzini MA, De Silvestri A, et al No evidence of autoimmunity in 6-year-old children immunized at birth with recombinant hepatitis B vaccine. Pediatrics 110, e4 (2002).
  • Lewis E, Shinefield HR, Woodruff BA, et al Safety of neonatal hepatitis B vaccine administration. Pediatr Infect. Dis.. 1. 20, 1049–1054 (2001).
  • Jefferson T, Traversa G. Hepatitis B vaccination: risk-benefit profile and the role of systematic reviews in the assessment of causality of adverse events following immunization.. 1. Med. Virol. 67,451-453 (2002).
  • Ascherio A, Zhang SM, Hernan MA, etal. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl.. 1. Med. 344, 327–332 (2001).
  • ••This case-control study conducted in twolarge cohorts clearly demonstrates no association between hepatitis B vaccination and the development of multiple sclerosis.
  • Biroscak BJ, Fiore AE, Fasano N, Fineis P, Collins MP, Stoltman G. Impact of the thimerosal controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. Pediatrics iii, e645-649 (2003).
  • Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N EngL Med. 315,209–214 (1986).
  • Koff RS. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 20,3695–3701 (2002).
  • Fitz Simons D, Francois G, Emiroglu N, Van Damme P Combined hepatitis B vaccines. Vaccine 21,1310–1316 (2003).
  • Tada H, Yanagida M, Mishina J, et al. Combined passive and active immunization for preventing perinatal transmission of hepatitis B virus carrier state. Pediatrics 70, 613–619 (1982).
  • Euler GL, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting and preventing perinatal transmission. Pediatrics 111, 1192–1197 (2003).
  • del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 15,1624–1630 (1997).
  • •This paper shows that the protective efficacy rate of HBV passive-active immunization is related to the maternal HBV DNA
  • Milne A, West DJ, Chinh DV, Moyes CD, Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants.. 1. Med. Virol. 67,327-333 (2002).
  • Strine TVV, Barker LE, Mokdad AH, Luman ET, Sutter RVV, Chu SY. Vaccination coverage of foreign-born children 19 to 35 months of age: findings from the National Immunization Survey, 1999–2000. Pediatrics 110, el5 (2002).
  • Zhu Q, Lu Q, Gu X, Xu H, Duan S. A preliminary study on interruption of HBV transmission in uterus. Chin. Med.. 1. 110, 145–147 (1997).
  • Zhu Q, Yu G, Yu H, et al. A randomized control trial on interruption of HBV transmission in uterus. Chin. Med.. 1. 116, 685–687 (2003).
  • Chen DS. Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region.. 1. GastroenteroL HepatoL 15 (Suppl.), E7—E10 (2000).
  • Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl.. 1. Med. 336,1855-1859 (1997).
  • Anonymous. Hepatitis B vaccination — United States, 1982–2002. MMWR Morb. Mortal. Wkly Rep. 51,549-552,563 (2002).
  • Mast EE, Mahoney FJ, Alter MJ, Margolis HS. Progress toward elimination of hepatitis B virus transmission in the United States. Vacdne 16 (Suppl.), S48—S51 (1998).
  • Papaevangelou G. Hepatitis B immunization programme: lessons learnt in Greece. Vaccine 16(Suppl.), S45—S47 (1998).
  • Zamir C, Dagan R, Zamir D, et al Evaluation of screening for hepatitis B surface antigen during pregnancy in a population with a high prevalence of hepatitis B surface antigen-positive/hepatitis B e antigen-negative carriers. Pediatr Infect. Dis. J 18, 262–266 (1999).
  • Da Villa G, Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 17,1734–1738 (1999).
  • Da Villa G. Rationale for the infant and adolescent vaccination programmes in Italy. Vaccine 18 Suppl. 1, S31-34 (2000).
  • Stroffolini T, Bianco E, Szklo A, et al. Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy. Vaccine 21, 1246–1249 (2003).
  • Bonanni P, Pesavento G, Bechini A, et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 21,685–691 (2003).
  • Mele A. Progress in prevention and control of hepatitis B: a congress reviewing the first ten years since the introduction of mass vaccination in Italy. J Med. ViroL 67,432 (2002).
  • Mele A, Stroffolini T, Zanetti AR. Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. J Med. ViroL 67,440–443 (2002).
  • Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine 18 Suppl. 1, S35-38 (2000).
  • •The authors report the remarkable results obtained after universal hepatitis B vaccination in Taiwan.
  • Lin HH, Kao JH, Chang TC, Hsu HY, Chen DS. Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. J Med. ViroL 69,466–470 (2003).
  • Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr. 139,349–352 (2001).
  • Kane MA. Status of hepatitis B immunization programmes in 1998. Vaccine 16 Suppl, S104-108 (1998).
  • Maddrey WC. Hepatitis B: an important public health issue. J Med. Virol. 61, 362–366 (2000).
  • Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001.1 Med. ViroL 67,433–439 (2002).
  • Fitz Simons D, Van Damme P, Emiroglu N, et al. Strengthening immunization systems and introduction of hepatitis B vaccine in central and eastern Europe and the newly independent states. Vaccine 20, 1475–1479 (2002).
  • Vranckx R, Alisjahbana A, Meheus A. Hepatitis B virus vaccination and antenatal transmission of HBV markers to neonates. J Viral Hepat. 6,135–139 (1999).
  • •The authors analyse the protective rate after HBV vaccination of neonates born from 61 HBsAg positive mothers.
  • Euler GL, Copeland JR, Rangel MC, Williams WW Antibody response to postexposure prophylaxis in infants born to hepatitis B surface antigen-positive women. Pediatr. Infect. Dis. 22,123–129 (2003).
  • Mele A, Tancredi F, Romano L, et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect. Dis. 184, 905–908 (2001).
  • Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J. Infect. Dis. 187, 134–138 (2003).
  • Reifenberg K, Deutschle T, Wild J, et al. The hepatitis B virus e antigen cannot pass the murine placenta efficiently and does not induce CTL immune tolerance in H-2b mice in utero. Virology243,45-53 (1998).
  • Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin. Infect. Dis. 27,100–106 (1998).
  • Nainan OV, Khristova ML, Byun K, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J. Med. ViroL 68,319–327 (2002).
  • Ngui SL, O'Connell S, Eglin RP, Heptonstall J, Teo CG. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. Infect. Dis. 176,1360–1365 (1997).
  • Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13,699–702 (1995).
  • Zhou F, Euler GL, McPhee SJ, etal. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese-American children and adolescents in Houston and Dallas. Pediatrics111, 1289–1296 (2003).
  • Alberti A, Brunetto MR, Colombo M, Craxi A. Recent progress and new trends in the treatment of hepatitis B. J. Med. ViroL 67, 458–462 (2002).
  • Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. EngL Med. 339,61–68 (1998).
  • Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Cilia. Pharrnacokinet. 36,41–66 (1999).
  • Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet359,1488-1489 (2002).
  • van Zonneveld M, van Nunen AB, Niesters HG, et al Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 10,294–297 (2003).
  • •The authors describe the significant decrease of HBV transmission when lamivudine treatment is established during the last month of pregnancy in women with high viral load, this treatment being associated with immunisation of neonate.
  • Li XM, Yang YB, Hou HY, et al. Interruption of HBV intrauterine transmission: A clinical study. Wor]dj GastroenteroL 9,1501–1503 (2003).
  • De Clercq E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Rev Anti-infect. Ther. 1,21–43 (2003).

Websites

  • Information on hepatitis B disease, epidemiology and immunization is available from the World Health Organization: www.who.int
  • Information regarding the safety of hepatitis B vaccines can be obtained from the Centre for Diseases Control: www.cdc.gov
  • A vast quantity of HBV information is also supplied by the Immunization Action Coalition: www.immunize.org

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.